We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Promotes Evidence MultiSTAT Automated Benchtop Immunoassay Analyzer

By Theresa Herman, Regional Director
Posted on 31 Jan 2019
Image: The Evidence MultiSTAT analyzer (Photo courtesy of Randox Laboratories).
Image: The Evidence MultiSTAT analyzer (Photo courtesy of Randox Laboratories).
Randox Laboratories (Crumlin, UK) participated in MedLab Middle East 2019 held in Dubai, UAE, from February 4-7, 2019, where it offered live product demonstrations of the Evidence MultiSTAT automated benchtop immunoassay analyzer.

The Evidence MultiSTAT simultaneously detects up to 21 classical, prescription and synthetic drugs from a single patient sample. Utilizing revolutionary Biochip Array Technology, it uses a chemiluminescence reaction as a measuring principle to ensure consistently accurate results. Moving away from traditional single analyte assays, Biochip Array Technology boasts of cutting-edge multiplex testing capabilities providing rapid and accurate drug detection from a single sample. Biochip Array Technology has a proven high standard of accurate test results with CVs typically <10% with a 98% agreement with confirmatory methods.

Based on ELISA principles, the biochip is a solid-state device with discrete test sites onto which antibodies specific to different drug compounds are immobilized and stabilized. Competitive chemiluminescent immunoassays are then employed, offering a highly sensitive screen. Testing panels are available for blood and urine samples to accommodate various testing requirements, with a minimal 200ul sample volume required, ensuring more sample is available for confirmatory testing.

Randox has the world’s largest toxicology test menu, with the ability to detect over 500 drugs and drug metabolites. Randox also has the world’s most advanced drug screening test menu spanning a wide range of classical, prescription and synthetic drugs of abuse. The Evidence Multistat provides a complete drug profile in one simple process, reducing the amount of time and labor spent on individual tests. The reliability and accuracy of results also reduces the financial burden of re-testing. With multiple results obtained in less than 20 minutes, the Evidence MultiSTAT is an ideal analyzer for emergency drugs of abuse screening.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System

Channels

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image Credit: Adobe Stock

Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer

Gastroesophageal adenocarcinoma comprises a group of aggressive cancers that are often diagnosed at an advanced stage and carry poor prognoses. Gastric and esophageal cancers rank among the leading causes... Read more